Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program

Following the results of the IMpassion130 trial, an early access program (EAP) was opened in France, allowing patients with PD-L1-positive advanced triple negative breast cancer (aTNBC) to receive a combination of paclitaxel and atezolizumab as first line therapy. This EAP was later discontinued whe...

Descripción completa

Detalles Bibliográficos
Autores principales: de Moura, Alexandre, Vuagnat, Perrine, Renouf, Benjamin, Pierga, Jean-Yves, Loirat, Delphine, Vaflard, Pauline, Lafayolle de la Bruyère, Charline, Chaumard-Billotey, Natacha, Hajjaji, Nawale, Ladoire, Sylvain, Dabakuyo, Sandrine, Patsouris, Anne, Frenel, Jean Sébastien, Nicolai, Vincent, Alexandre, Marie, Dohollou, Nadine, Grenier, Julien, Bourien, Heloïse, Bidard, François-Clément
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439112/
https://www.ncbi.nlm.nih.gov/pubmed/37596388
http://dx.doi.org/10.1038/s41598-023-40569-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439112/
https://www.ncbi.nlm.nih.gov/pubmed/37596388
http://dx.doi.org/10.1038/s41598-023-40569-9

Ejemplares similares